We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Atmos Energy
ATO
$29.9B
| $280K | ﹤0.01% |
2,516
+530
| +27% | +$58.1K |
|
927
Pinnacle Financial Partners Inc
PNFP
$15.9B
| $279K | ﹤0.01% |
4,382
+52
| +1% | +$3.14K |
|
928
Pool Corp
POOL
$7B
| $279K | ﹤0.01% |
1,314
-77
| -6% | -$15.9K |
|
929
Regions Financial
RF
$26.7B
| $279K | ﹤0.01% |
16,377
-3,078
| -16% | -$50.7K |
|
930
Zebra Technologies
ZBRA
$13.5B
| $277K | ﹤0.01% |
1,086
+121
| +13% | +$28.3K |
|
931
Werner Enterprises
WERN
$2.3B
| $275K | ﹤0.01% |
7,575
-940
| -11% | -$34.4K |
|
|
RDS.B
932
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $274K | ﹤0.01% |
4,601
-2,880
| -38% | -$170K |
|
|
DISH
933
DELISTED
DISH Network Corp.
DISH
| $274K | ﹤0.01% |
7,748
-2,821
| -27% | -$97.7K |
|
|
SPR
934
DELISTED
Spirit AeroSystems
SPR
| $272K | ﹤0.01% |
3,753
-1,724
| -31% | -$142K |
|
935
Sarepta Therapeutics
SRPT
$1.63B
| $272K | ﹤0.01% |
2,109
| – | – |
|
936
First Financial Bankshares
FFIN
$5.05B
| $271K | ﹤0.01% |
7,736
| – | – |
|
937
GDS Holdings
GDS
$6.14B
| $270K | ﹤0.01% |
5,244
-1,032
| -16% | -$46.2K |
|
|
IFX
938
DELISTED
INFINEON TECH AG ADS(REP1 ORD)
IFX
| $270K | ﹤0.01% |
11,874
+278
| +2% | +$6.32K |
|
939
Fulton Financial
FULT
$4.73B
| $269K | ﹤0.01% |
15,469
| – | – |
|
940
Southern Copper
SCCO
$140B
| $269K | ﹤0.01% |
6,864
| – | – |
|
|
AZ
941
DELISTED
Allianz Se Sponsored Adr Repstg 1/10 Ord Sh
AZ
| $269K | ﹤0.01% |
10,994
-138,777
| -93% | -$3.4M |
|
942
Trip.com Group
TCOM
$28.5B
| $266K | ﹤0.01% |
7,932
+4,283
| +117% | +$138K |
|
943
Paylocity
PCTY
$7.43B
| $265K | ﹤0.01% |
2,204
-311
| -12% | -$34.1K |
|
|
DCPH
944
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $264K | ﹤0.01% |
4,249
+199
| +5% | +$9.46K |
|
945
Integra LifeSciences
IART
$1.54B
| $263K | ﹤0.01% |
4,516
+21
| +0.5% | +$1.25K |
|
|
LOGM
946
DELISTED
LogMein, Inc.
LOGM
| $263K | ﹤0.01% |
3,081
+2,483
| +415% | +$184K |
|
947
CONMED
CNMD
$1.33B
| $262K | ﹤0.01% |
2,350
+32
| +1% | +$3.41K |
|
948
Blackstone Mortgage Trust
BXMT
$2.81B
| $260K | ﹤0.01% |
7,034
+134
| +2% | +$4.88K |
|
949
WisdomTree Europe Hedged Equity Fund
HEDJ
$1.83B
| $258K | ﹤0.01% |
7,330
-564
| -7% | -$19.4K |
|
950
Chemours
CC
$2.57B
| $256K | ﹤0.01% |
14,244
-992
| -7% | -$16.5K |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.